Search results for " Purpura"

showing 10 items of 66 documents

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies.

2020

AbstractThree selected casuistic studies of individual patient problems from my long-standing professional experience are presented. I intend to highlight the potential contribution of case studies, including new approaches of laboratory investigation, for the advancement of pathophysiological knowledge and would encourage to “rehabilitate” the low academic profile generally attributed to “case reports.”

AdultMalemedicine.medical_specialtybusiness.industrymedicine.drug_classThrombotic thrombocytopenic purpuraMEDLINEHematology030204 cardiovascular system & hematologyVitamin K antagonistmedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisMedicineHumansFemalebusinessIntensive care medicineLaboratoriesProblem SolvingHamostaseologie
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Characterization of the Teeth Skeletal Matrix from <i>Arbacia lixula</i>

2016

The teeth of sea urchins are highly complex composite structures, composed predominantly of high magnesium calcite, and of a minor heterogeneous assemblage of organic macromolecules that are occluded within the mineral. The organic matrix fulfils important functions in mineralization, in addition to giving the mineral phase peculiar mechanical properties, different from that of purely inorganic calcite. Nevertheless, the composition and function of individual components of the organic matrix still remains largely unknown. Up to now, the detailed protein repertoire of teeth from a single sea urchin species (Strongylocentrotus purpuratus, order Camarodonta) was investigated. In this study, we…

AlanineCalcitebiologyChemistryMechanical EngineeringArbacioidabiology.organism_classificationStrongylocentrotus purpuratusMineralization (biology)chemistry.chemical_compoundBiochemistryMechanics of Materialsbiology.animalGeneral Materials ScienceSea urchinArbacia lixulaBiomineralizationKey Engineering Materials
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct

Evaluation of Clotting Factor Concentrates for Treatment of Thrombotic Thrombocytopenic Purpura.

2010

Abstract Abstract 3678 Introduction: Thrombotic thrombocytopenic purpura (TTP) is characterized by microthrombi, hemolytic anemia as well as thrombocytopenia. These symptoms are caused by a decreased activity of the protease ADAMTS13 which cleaves the von Willebrand Factor (VWF), due to mutation of the ADAMTS13-gene or autoantibodies. At the moment, the only available immediate therapy is plasmapheresis with Fresh Frozen Plasma (FFP) which may induce side effects. Therefore an alternative therapy might be the treatment with clotting factor concentrates. Methods: 40 plasma samples were tested, consisting of FFP and solvent/detergent treated plasma, four batches of each blood group; VWF/VIII …

Clotting factorHemolytic anemiamedicine.medical_specialtybiologyChemistrymedicine.medical_treatmentImmunologyAutoantibodyThrombotic thrombocytopenic purpuraCell BiologyHematologymedicine.diseaseBiochemistryADAMTS13EndocrinologyVon Willebrand factorhemic and lymphatic diseasesInternal medicineImmunologymedicinebiology.proteinPlasmapheresisFresh frozen plasmaBlood
researchProduct

Echinoderm Antimicrobial Peptides

2016

Abstract Antimicrobial peptides (AMPs) are widely expressed in organisms and have been linked to innate and acquired immunity in vertebrates. These compounds are constitutively expressed from different cellular types to interact directly with infectious agents and/or modulate immunoreactions. In invertebrates, including echinoderms, which lack a vertebrate-type adaptive immune system, AMPs represent the major humoral defense system against infection, showing a diverse spectrum of action mechanisms, most of them related to plasma membrane disturbance and lethal alteration of microbial integrity. Here, we summarize the knowledge of AMPs in echinoderms as Strongylocins identified in the sea ur…

DeuterostomeImmune systemInnate immune systembiologyEchinodermHolothuria tubulosaAntimicrobial peptidesbiology.organism_classificationAcquired immune systemStrongylocentrotus purpuratusCell biology
researchProduct

Karyological data of four geophytes native to Tunisia

2021

Chromosome numbers were studied in four geophytes collected in Tunisia. Allium pallens was collected from Zembra island, N of Tunisia, while Drimia purpurascens, Oncostema peruvianum and Pancratium foetidum from continental Tunisia. The chromosome numbers found for Allium pallens, Drimia purpurascens, and Oncostema peruvianum coincides with the previous reports obtained from other Mediterranean populations. The chromosome number 2n = 22, found on material from Toujane is the first reported for Pancratium foetidum.

Drimia purpurascenOncostema peruvianumSettore BIO/02 - Botanica SistematicaAllium pallenPancratium foetidumPlant ScienceNorth AfricaChromosome number
researchProduct

Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Span…

2019

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, but life-threatening, hematological disorder characterized by severe thrombocytopenia, hemolytic microangiopathic anemia, and frequent organ damage. The underlying pathophysiology of aTTP is a functional deficiency of plasma ADAMTS13 activity caused by antibodies directed against the ADAMTS13 protease. Despite plasma exchange (PEX) and immunosuppression with corticosteroids, and, more recently, rituximab, which achieve remission in most patients with aTTP, 10-20% of patients are refractory to treatment and die as a result of disease progression. Most of such deaths occur during first episodes of aTTP, as subsequent…

First episodemedicine.medical_specialtyAcquired Thrombotic Thrombocytopenic PurpuraExacerbationbusiness.industryStuporImmunologyThrombotic thrombocytopenic purpuraCell BiologyHematologymedicine.diseaseBiochemistryADAMTS13Platelet transfusionInternal medicinemedicineRituximabmedicine.symptombusinessmedicine.drugBlood
researchProduct

Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report

2015

Dear Editor, In the current clinical practice, minimal criteria to define thrombotic thrombocytopenic purpura (TTP) are the presence of signs of microangiopathic haemolytic anaemia and low platelet (PLT) count [1]. TTP relapses (20–50 % of cases) are defined as the recurrence of acute TTP symptoms 30 days after the first episode, while exacerbations occur within 30 days [2]. We here report on an atypical case of acquired TTP where minimal criteria were met only after many recurrent macrovascular ischemic events. A 42-year old Caucasian woman with a history of coronary and cerebral ischemic events was admitted on June 2013, following a recurrent transient ischemic attack (TIA). She had sever…

First episodemedicine.medical_specialtybusiness.industryThrombotic thrombocytopenic purpuraHematologyGeneral MedicineGene mutationmedicine.diseaseGastroenterologyAtypical Thrombotic Thrombocytopenic purpuraADAMTS13Schistocytehemic and lymphatic diseasesInternal medicinemedicineFactor V LeidenRituximabbusinessStrokemedicine.drugAnnals of Hematology
researchProduct

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura

2014

SummaryWe report on our patient (case 2) who experienced a first acute episode of thrombotic thrombocytopenic purpura (TTP) at the age of 19 years during her first pregnancy in 1976 which ended in a spontaneous abortion in the 30th gestational week. Treatment with red blood cell concentrates was implemented and splenectomy was performed. After having suffered from several TTP episodes in 1977, possibly mitigated by acetylsalicylic acid therapy, an interruption and sterilization were performed in 1980 in her second pregnancy thereby avoiding another disease flare-up. Her elder sister (case 1) had been diagnosed with TTP in 1974, also during her first pregnancy. She died in 1977 during her se…

Genetic Markersmedicine.medical_specialtyPediatricsmedicine.medical_treatmentSplenectomyThrombotic thrombocytopenic purpuraADAMTS13 ProteinLate onsetCongenital Thrombotic Thrombocytopenic Purpura030204 cardiovascular system & hematologyAbortionYoung Adult03 medical and health sciences0302 clinical medicinePregnancyhemic and lymphatic diseasesHumansMedicineGenetic Testing610 Medicine & healthPregnancyPurpura Thrombotic Thrombocytopenicbusiness.industryPregnancy Complications HematologicHematologymedicine.diseaseADAMTS13SurgeryADAM Proteins030220 oncology & carcinogenesisGestationFemalebusinessHämostaseologie
researchProduct